2-溴-N-甲基苯甲酰胺 | 61436-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-N-甲基苯甲酰胺
• 中文别名: N-甲基-2-溴苯甲酰胺；2-溴-N-甲基苯酰胺
• 英文名称: 2-bromo-N-methylbenzamide
• 英文别名: N-methyl 2-bromobenzamide
• CAS: 61436-88-2
• 化学式: C₈H₈BrNO
• mdl: MFCD00099250
• 分子量: 214.062
• InChiKey: FKVCJQNPXXXZIE-UHFFFAOYSA-N

物化性质

• 熔点：
  143-146
• 保留指数：
  1666
• 稳定性/保质期：
  避免接触氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  在密封的贮藏器中存放，并置于阴凉、干燥处保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Methyl 2-bromobenzamide
Product Name:
Synonyms: 2-Bromo-N-methylbenzamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Methyl 2-bromobenzamide
Ingredient name:
CAS number: 61436-88-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BrNO
Molecular weight: 214.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-N-甲基苯甲酰胺 在 N-溴代丁二酰亚胺(NBS) 、 叔丁基氯化镁 、 四丁基氟化铵 、 silver fluoride 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 32.0h， 生成 2-(benzoylamino)-1-phenylethanol
  参考文献：
  名称：

  [1,5]-氢转移介导的脂肪族CH键的位点选择性硅烷化：α-Sila苯甲酰胺的合成

  摘要：

  报道了由[1,5]-氢转移介导的C（sp 3）-H键的位点选择性甲硅烷基化的第一个例子。该反应选择性地在苯甲酰胺的α-位与叔丁基氯化镁和催化量的4,4'-二叔丁基联吡啶（dtbpy）配体结合而发生，并提供了一条容易的途径来产生具有生物学意义的α -sila苯甲酰胺。掺入的甲硅烷基部分的后期官能化促进了N-甲酰基，顺式-烯胺，β-羟基，氨基和含吡咯的衍生物的合成。

  DOI：

  10.1021/acs.orglett.6b02784
• 作为产物：
  描述：

  N-甲基苯甲酰胺 在 N-溴代丁二酰亚胺(NBS) 、 silver hexafluoroantimonate 、 三氟甲磺酸 、 nickel diacetate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 12.0h， 以73%的产率得到2-溴-N-甲基苯甲酰胺
  参考文献：
  名称：

  缺电子芳烃的镍催化区域选择性C–H卤化†

  摘要：

  开发了一种简单的Ni（II）催化的一般策略，用于用易获得的卤化试剂N-卤代琥珀酰亚胺（NXS; X = Br，Cl和I）对电子缺陷型芳烃进行邻卤代化。该转化是高度区域选择性的，并且观察到宽的底物范围和官能团耐受性。该发现对于酰胺，苯甲酸酯和其他具有引导基团的物质的选择性卤化可能具有重要意义。还介绍了机械研究。

  DOI：

  10.1039/c8nj06023a

文献信息

• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：US20190330198A1

  公开（公告）日：2019-10-31

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• [EN] 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG<br/>[FR] DÉRIVÉS DE 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE EN TANT QU'INHIBITEURS DE LA PARG
  申请人：CANCER REC TECH LTD

  公开号：WO2016092326A1

  公开（公告）日：2016-06-16

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（Poly ADP-ribose glycohydrolase）酶活性抑制剂的I式化合物，其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及PARG活性的疾病或症状中的用途。
• Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides
  作者：Bohdan Waszkowycz、Kate M. Smith、Alison E. McGonagle、Allan M. Jordan、Ben Acton、Emma E. Fairweather、Louise A. Griffiths、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Colin P. Hutton、Dominic I. James、Clifford D. Jones、Stuart Jones、Daniel P. Mould、Helen F. Small、Alexandra I. J. Stowell、Julie A. Tucker、Ian D. Waddell、Donald J. Ogilvie

  DOI：10.1021/acs.jmedchem.8b01407

  日期：2018.12.13

  DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential

  DNA损伤修复酶是开发用于多种癌症和其他潜在疾病的新型治疗剂的有希望的目标。聚（ADP-核糖）糖水解酶（PARG）在调节DNA修复机制中起着关键作用。然而，由于缺乏用于细胞和体内模型的有效药物样抑制剂，限制了其作为新型治疗靶标的潜力的研究。通过将人类PARG的晶体结构与弱活性和具有细胞毒性的蒽醌8a配合使用，已通过基于结构的虚拟筛选和库设计方法鉴定了新型喹唑啉二酮磺酰胺类PARG抑制剂。1-氧杂-3-基甲基衍生物33d和35d选择用于体内的初步研究。X射线晶体结构有助于合理化所观察到的这些新型抑制剂的构效关系。
• Rhodium(iii)-catalyzed oxidative carbonylation of benzamides with carbon monoxide
  作者：Ya Du、Todd K. Hyster、Tomislav Rovis

  DOI：10.1039/c1cc15843k

  日期：——

  An efficient strategy for the oxidative carbonylation of aromatic amidesvia C–H/N–H activation to form phthalimides using an Rh(III) catalyst has been developed. The reaction shows a preference for C–H bonds of electron-rich aromatic amides and tolerates a variety of functional groups.

  开发了一种通过C-H/N-H活化，利用Rh(III)催化剂高效地将芳香酰胺氧化羰基化合成酞菁的策略。该反应倾向于电子丰富的芳香酰胺的C-H键，并能容忍多种官能团。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。